Inovio Pharmaceuticals (NASDAQ: INO) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and ...
What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device According to the complaint, ...
Shares of Inovio Pharmaceuticals Inc. INO shed 6.67% to $1.26 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.19% ...
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are trading lower by 40% to $2.23 during Friday’s session after the company priced a public offering of 10 million shares of common stock and ...
Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering ...
Analysts' ratings for Inovio Pharmaceuticals (NASDAQ:INO) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings ...
Hosted on MSN
Inovio (INO) Upgraded to Buy: Here's Why
Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
What: Shares of Inovio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing synthetic vaccines to treat cancer as well as various types of infectious diseases, plunged 15% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results